QT Imaging Holdings, Inc.

What they do

QT Imaging develops and commercializes body imaging systems using ultra-low-frequency transmitted sound, with its current product being the Breast Acoustic CT scanner, a Class II 510(k)-cleared device. The scanner produces 3D volumetric images of breast tissue without ionizing radiation or breast compression, using a sound back-scatter design and inverse-scattering reconstruction algorithms. The company was founded in 2012, went public through a SPAC merger with GigCapital5 in March 2024, and has received nearly $18 million in NIH financial support over its history.

Revenue drivers

• Breast Acoustic CT scanner sales — The core revenue line: 15 scanners shipped in Q2 2026 and 28 in the first half of 2026, producing $7.4 million of Q2 revenue and $14.0 million for the half.
• Distribution partners — The company sells through established distribution partnerships alongside its own commercial team, which the Q2 release describes as complementary channels for driving scanner adoption.
• Geographic expansion — Revenue now includes international placements, with recent regulatory authorizations in Israel and Saudi Arabia and ongoing pursuit of authorizations in the Gulf region and Europe.

Recent performance

Q2 2026 revenue was $7.4 million with 15 scanners shipped, versus 8 scanners in the prior-year period, and first-half revenue rose 116% to $14.0 million. Full-year 2025 revenue was $18.9 million against a net loss of $21.1 million, compared with $4.9 million of revenue and a $9.0 million net loss in 2024. Operating cash flow was negative $9.0 million in 2025 and negative $10.0 million in 2024. At June 30, 2026, total assets were $30.6 million, total liabilities $28.4 million, shareholder equity $2.2 million, and cash and equivalents $10.9 million, with $11.4 million of long-term debt.

Strategy

Management is scaling commercial operations by combining distribution partners with an expanded direct U.S. sales organization, including a Chief Commercial Officer and two regional sales vice presidents appointed in 2026. The company raised approximately $10.0 million in gross proceeds from an underwritten public offering in Q2 2026 and extended its senior secured term loan maturity by two years, from March 31, 2027, to March 31, 2029. It expanded manufacturing capacity with a new 22,000-square-foot facility and completed its first routine FDA inspection with zero Form 483 observations. QT Imaging is also building out a quantitative breast imaging platform spanning hardware, software and cloud infrastructure, with AI-enabled clinical applications contemplated over time. More than 12,000 women have been imaged with the technology to date.

Risks

• Development-stage with significant losses — The company describes itself as a development-stage business with limited operating history and significant losses since inception, having lost $21.1 million in 2025 alone.
• Unproven at larger commercial scale — Management states it has demonstrated commercial viability at scales of tens of scanners but not yet at larger scales, leaving the scalability of the business model unproven.
• Thin equity and cash position — Shareholder equity was only $2.2 million at June 30, 2026 against $28.4 million of liabilities, so any operating shortfall could rapidly pressure the balance sheet.
• Geopolitical exposure in the Gulf region — Management stated that geopolitical developments have impacted commercial activities in parts of the Gulf region, where it is pursuing new regulatory authorizations.

Outlook

Management reaffirmed full-year 2026 revenue guidance of approximately $39 million in the August 2026 earnings release. It cited encouraging signs of renewed customer engagement in the Gulf region following geopolitical disruption and said it continues to pursue additional regulatory authorizations in the Gulf region and Europe. The company also pointed to its expanded U.S. commercial organization and new manufacturing facility as foundations for scaling Breast Acoustic CT adoption.